Syntara Secures Fresh Capital to Advance Clinical Pipeline
Syntara Limited (ASX: SNT) has strengthened its financial position through a capital raising of AU$8 million via an institutional placement, alongside plans to raise an additional AU$2 million through a share purchase plan. The funding follows encouraging regulatory feedback supporting the design of its Phase 2b trial for its lead drug candidate targeting myelofibrosis.
The new capital will support multiple clinical milestones, including five anticipated trial readouts in 2026, as well as preparation for the upcoming Phase 2b study. Funds will also be allocated to advancing licensing discussions and expanding the company’s intellectual property portfolio. Shares were issued at AU$0.027, representing a discount to recent trading levels, with approximately 296 million new shares to be released in two stages. With an extended cash runway into 2027, Syntara is positioned to progress its clinical programs and explore commercial opportunities across its drug development pipeline.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Syntara Secures Fresh Capital to Advance Clinical Pipeline
Syntara Limited (ASX: SNT) has strengthened its financial position through a capital raising of AU$8 million via an institutional placement, alongside plans to raise an additional AU$2 million through a share purchase plan. The funding follows encouraging regulatory feedback supporting the design of its Phase 2b trial for its lead drug candidate targeting myelofibrosis.
The new capital will support multiple clinical milestones, including five anticipated trial readouts in 2026, as well as preparation for the upcoming Phase 2b study. Funds will also be allocated to advancing licensing discussions and expanding the company’s intellectual property portfolio. Shares were issued at AU$0.027, representing a discount to recent trading levels, with approximately 296 million new shares to be released in two stages. With an extended cash runway into 2027, Syntara is positioned to progress its clinical programs and explore commercial opportunities across its drug development pipeline.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au